灯盏花素和丹参注射液治疗冠心病心绞痛患者有效性及安全性的Meta分析

doi:10.13481/j.1671-587x.20170220

摘要/Abstract

摘要： 目的：应用Meta分析方法对比灯盏花素与丹参注射液治疗冠心病心绞痛患者的有效性及安全性，为临床用药提供依据。方法：计算机检索Cochrane试验资料库、Ovid-Medline全文数据库、EMBase数据库、PubMed数据库、中国学术文献总库（CNKI）、万方数字化期刊库，维普数据库（VIP）及中国生物医学文献数据库（CBM），获得有关灯盏花素和丹参注射液治疗冠心病心绞痛患者有效性及安全性的文献，根据入选与剔除原则筛选文献、评价文献质量，提取相关数据，应用RevMan 5.3软件进行Meta分析。结果：初步检索出167篇文献，根据选取标准共8篇有关灯盏花素和丹参注射液治疗冠心病心绞痛的随机对照研究符合入选标准。缓解症状疗效分析，χ²=2.62，df=7，P=0.92，Z=6.85，95%CI：2.73~6.10；心电图疗效分析，χ²=6.37，df=7，P=0.50，Z=6.37 （P=0.00001），95%CI：1.94~3.49。2种药物治疗冠心病心绞痛均无明显不良反应。Meta分析，灯盏花素和丹参注射液治疗冠心病心绞痛患者在缓解症状及改善心电图疗效方面比较差异有统计学意义（P<0.05）。结论：与丹参注射液比较，灯盏花素治疗冠心病心绞痛具有更好的疗效，且二者均无明显不良反应。

关键词: 心绞痛, 灯盏花素注射液, 丹参注射液, Meta分析, 冠心病

Abstract: Objective: To compare the effectiveness and safety of Dengzhanhuasu and Danshen Injection in the treatment of the patients with angina pectoris of coronary heart disease with Meta-analysis, and to provide basis for their application in clinic. Methods: Computer search was performed using Cochrane Central Register of Controlled Trial,Ovid-medline,EMBASE,PubMed,CNKI,Wanfang,VIP and CBM,and the literatures about the effectiveness and safety of Dengzhanhuasu and Dansheng Injection in the treatment of the patients with angina pectonis of coronary heart disease were obtained. According to the principle of selection and elimination, the literatures were selected, and the qualities of literatures were evaluated. The related data were extracted from the literatures.RevMan 5.3 software was used to extract the data for Meta-analysis. Results: A total of 167 literatures were retrieved, and 8 randomlized-controlled studies were selected according to the selection criteria. The evaluation results of the effectiveness of angina pectoris according to symptom showed that χ²=2.62,df=7,P=0.92,Z=6.85 (P<0.000 01), 95%CI:2.73-6.10. The evaluation of the effectiveness of angina pectoris according to electrocardiogram,χ²=6.37,df=7,P=0.50,Z=6.37(P=0.000 01),95%CI:1.94-3.49.The results of Meta-analysis showed that there were significant differences in the relief of symptoms and improvement of the electrocardiogram efficacy between Dengzhanhuasu and Danshen Injection in the treatment of angina pectoris of coronary heart disease (P<0.05). Conclusion: Dengzhanhuasu has better effectiveness in the treatment of the patients with unstable angina than Dansheng Injection and they have the same safety.

Key words: angina pectoris, Dengzhanhuasu Injection, Danshen Injection, Meta-analysis, coronary heart disease

中图分类号:

R541.4

张洋, 王俊峰, 曹鸿雁, 秦玲, 徐国良. 灯盏花素和丹参注射液治疗冠心病心绞痛患者有效性及安全性的Meta分析[J]. 吉林大学学报(医学版), 2017, 43(02): 317-321.

ZHANG Yang, WANG Junfeng, CAOHongyan, QIN Ling, XU Guoliang. Effectiveness and safety of Dengzhanhuasu and Dansheng Injection in treatment of patients with angina pectoris of coronary heart disease:A Meta-analysis[J]. Journal of Jilin University Medicine Edition, 2017, 43(02): 317-321.

参考文献

[1] 王辰,王建安.内科学[M ].北京:人民卫生出版社, 2015:296.
[2] 孙建峰,徐彩云,宫余静,等. 山楂叶总黄酮对实验性心肌梗死犬的保护作用[J].吉林大学学报:医学版,2016,42(1):76-79.
[3] 张宜春,徐岩,辜和平. 脂蛋白(a)水平与VH-IVUS检测冠脉粥样硬化斑块成分的关联性分析[J].吉林大学学报:医学版,2016,42(1):115-119.
[4] Li Q,Wu JH,Guo DJ,et al.Suppression of diet-induced hypercholesterolemia by scutellarin inrats[J].Planta Med,2009,75 (11):1203-1208.
[5] He M,Xue ZM,Li J,et al.Breviscapine inhibits high glucose-induced proliferation and migration ofcultured vascular smooth muscle cells of rats via suppressing the ERK1/2 MAPK signalingpathway[J].Acta Pharmacol Sin,2012,33(5):606-614.
[6] 贺运河,陈镜合.中药抗心肌缺血-再灌注损伤作用的机制研究现状[J].中西医结合心脑血管病杂志,2004,2(3):165-167.
[7] 1980年全国内科学术会议关于冠状动脉心脏病命名及诊断标准[J].中华内科杂志,1981, 20 (4):253-255.
[8] 中华人民共和国卫生部医政司.中国常见心脑血管疾病诊治指南[M ].北京:北京科学技术出版社, 2000:59-60.
[9] Sackett DL, Clarke M, Oxman AD, et al. Cochrane Reviewers, Handbook 4.2, In Renew Manager [M]. England:The Cochrane Collaboration, 2002:13-36.
[10] Jadad AR, Moore A, Carroll D, et al. Assessing the quality of reports of randomized clinical trials:is blinding necessary? [J]. Control Clin Trials, 1996, 17(1):1-12.
[11] 王宾,简伟翔,牛希文,等.灯盏花素注射液治疗冠心病心绞痛的疗效观察[J]. 国际医药卫生导报,2015,(15):26-27.
[12] 汤三红.灯盏花素注射液治疗冠心病心绞痛的疗效观察[J]. 中国农村卫生事业管理,2014, 34(2):230-231.
[13] 史强. 灯盏花素注射液治疗心绞痛80例临床观察[J]. 临床合理用药,2010,3(6):30-31.
[14] 刘宗贵. 灯盏花素注射液治疗冠心病心绞痛的疗效观察[J]. 临床合理用药,2009,2(17):54.
[15] 李香枝,格日勒,张伊晖,等.灯盏花素注射液治疗冠心病心绞痛60例疗效观察[J].内蒙古医学院学报,2005,27(4):311-312.
[16] 高祺,胡文杰. 灯盏花素注射液治疗冠心病心绞痛30例[J]. 陕西中医,2005,26(2):118-119.
[17] 牛俊辉,唐雁翔,齐敏. 灯盏花素注射液治疗冠心病心绞痛41例[J].中国民间疗法,2003,11(9):57.
[18] 聂元文,邢同国. 灯盏花素治疗冠心病心绞痛的疗效观察[J]. 菏泽医学专科学校学报,2002,14(2):36-37.
[19] 琼次仁,多布拉. 灯盏花素对不稳定型心绞痛患者血液流变学及血脂影响的Meta分析[J].西藏医药,2016(3):43-46.
[20] 张红祥,杨和金,包广雷,等. 灯盏花素主要药效学研究进展[J].云南中医中药杂志,2016,37(2):75-78.
[21] 陈丽芳. 灯盏花素治疗冠心病心绞痛的临床应用[J]. 中国循证心血管医学杂志,2016,8(4):500-502.
[22] 冯莉嵋,周元芳,李莉,等. 丹参多酚酸盐注射液与丹参注射液在冠心病治疗中的疗效和安全性对比[J]. 辽宁中医药大学学报,2016,8(11):183-185.
[23] 徐孝艳. 丹参注射液对冠心病心绞痛的治疗效果及药理探析[J].中国继续医学教育,2016,8(5):197-198.
[24] 董宠凯,马丙祥,王怡珍. 丹参注射液改善血流变学及凝血功能的实验研究进展[J]. 河南中医,2016,36(2):355-357.
[25] Egger M,Smith GD,Schneider M,et al.Bias in Meta-analysis detected by a simple, graphical test [J].Br Med J,1998,315(7):629-634.
[26] Bennett DA,Latham NK,Stretton C,et al. Anderson capture-recapture is a potentially useful method for assessing publication Bias[J].J Clin Epidemiol,2004,57(4):349-357.